Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.

Autor: Signoriello E; Multiple Sclerosis Center, Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy., Foschi M; Department of Neuroscience, MS Center-Neurology Unit, S. Maria Delle Croci Hospital, AUSL Romagna, Ravenna, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Lanzillo R; Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University, Naples, Italy., Frau J; Multiple Sclerosis Center, Department of Medical Sciences and Public Health University of Cagliari, Binaghi Hospital Cagliari/Italy, Cagliari, Italy., Cocco E; Multiple Sclerosis Center, Department of Medical Sciences and Public Health University of Cagliari, Binaghi Hospital Cagliari/Italy, Cagliari, Italy., Borriello G; San Pietro Fatebenefratelli-Hospital-MS Center Rome, Rome, Italy., Ianniello A; Department of Human Neuroscience, Sapienza University of Rome, Rome, Italy., Trotta M; Unit of Neurology A.O. Annunziata, Cosenza, Italy., Landi D; Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, University of Rome Tor Vergata, Tor VergataUniveristy Hospital, Rome, Italy., Maniscalco GT; Neurological Clinic and Multiple Sclerosis Center, A Cardarelli Hospital, Naples, Italy., Ruscica F; U.O.C. Neurologia E Centro SMFondazione Istituto G. Giglio, Cefalù, PA, Italy., Toscano S; Department 'GF Ingrassia', Section of Neurosciences, University of Catania, Catania, Italy., Patti F; Department 'GF Ingrassia', Section of Neurosciences, University of Catania, Catania, Italy., Zanghì A; Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., D'Amico E; Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Fantozzi R; Unit of Neurology, IRCCS Neuromed, Pozzilli, IS, Italy., Centonze D; Unit of Neurology, IRCCS Neuromed, Pozzilli, IS, Italy., Lus G; Multiple Sclerosis Center, Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy., Bonavita S; Multiple Sclerosis Center, Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy. simona.bonavita@unicampania.it.
Jazyk: angličtina
Zdroj: Journal of neurology [J Neurol] 2024 Jul; Vol. 271 (7), pp. 4039-4045. Date of Electronic Publication: 2024 Apr 03.
DOI: 10.1007/s00415-024-12291-7
Abstrakt: Introduction: Cladribine is an oral immune reconstitution therapy for relapsing multiple sclerosis (RMS). Hormonal and immune changes are responsible for the decline of disease activity in the third trimester of pregnancy and disease reactivation in the early post-partum period.We investigate the impact of pregnancy on disease activity in women with MS who conceived after cladribine treatment.
Methods: We recruited women of childbearing age with relapsing-remitting MS (RRMS) who became pregnant or not after being treated with cladribine. For both groups, demographic, clinical and radiological data were collected 1 year before and after treatment during a mean follow-up of 3.53 years. We compared disease activity over time between groups using variance analysis for repeated measures.
Results: 48 childbearing women were included. 25 women had a pregnancy after a mean of 1.75 years from the first treatment cycle. Women with or without pregnancy did not differ in demographics or pre-cladribine disease activity. No significant differences in disease activity or EDSS worsening were found between women with or without pregnancy.
Discussion: Our findings suggest that pregnancy does not appear to influence disease activity and disability in women previously treated with cladribine; further studies with larger numbers and longer follow-up are needed to confirm this finding.
(© 2024. The Author(s).)
Databáze: MEDLINE